Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Adult Participants With Peanut Allergy
NCT05432388Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of remibrutinib in peanut allergy (5 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Who Tolerated a Single Dose of >= 600 mg (1044 mg Cumulative Tolerated Dose) of Peanut Protein Without Dose-limiting Symptoms at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
remibrutinib
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05432388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432388.